Plasmepsin
From Proteopedia
(Difference between revisions)
Line 1: | Line 1: | ||
- | <StructureSection load='' size=' | + | <StructureSection load='' size='350' side='right' caption='Plasmepsin II complex with a potential antimalarial drug (PDB entry [[4cku]])' scene='44/441867/Cv/1'> |
== Function == | == Function == | ||
[[Plasmepsin]] (Plm) is a hemoglobin-degrading enzyme produced by the plasmodium parasite. It is an aspartic acid protease having 2 aspartic acid residues in the active site. Ten Plm isoforms are known which are named Plm I, II, etc and '''Histo-Aspartic Protease (HAP)'''. | [[Plasmepsin]] (Plm) is a hemoglobin-degrading enzyme produced by the plasmodium parasite. It is an aspartic acid protease having 2 aspartic acid residues in the active site. Ten Plm isoforms are known which are named Plm I, II, etc and '''Histo-Aspartic Protease (HAP)'''. | ||
Line 32: | Line 32: | ||
**[[3f9q]] – PfPlm II (mutant)<br /> | **[[3f9q]] – PfPlm II (mutant)<br /> | ||
**[[2r9b]] – PfPlm II + peptide inhibitor<br /> | **[[2r9b]] – PfPlm II + peptide inhibitor<br /> | ||
- | **[[1w6h]], [[2bju]], [[1lf2]], [[1lf3]], [[1lee]], [[2igx]], [[2igy]], [[4cku]], [[4y6m]], [[4z22]] – PfPlm II + inhibitor<br /> | + | **[[1w6h]], [[2bju]], [[1lf2]], [[1lf3]], [[1lee]], [[2igx]], [[2igy]], [[4cku]], [[4y6m]], [[4z22]], [[5yia]], [[5yib]], [[5yic]], [[5yid]], [[5yie]] – PfPlm II + inhibitor<br /> |
**[[4ya8]] – PfPlm II (mutant) + inhibitor<br /> | **[[4ya8]] – PfPlm II (mutant) + inhibitor<br /> | ||
**[[1w6i]], [[1xdh]], [[1xe5]], [[1xe6]], [[1me6]], [[1sme]] – PfPlm II + pepstatin derivative<br /> | **[[1w6i]], [[1xdh]], [[1xe5]], [[1xe6]], [[1me6]], [[1sme]] – PfPlm II + pepstatin derivative<br /> | ||
Line 41: | Line 41: | ||
**[[2anl]] – Plm IV + statine derivative – ''Plasmodium malariae''<br /> | **[[2anl]] – Plm IV + statine derivative – ''Plasmodium malariae''<br /> | ||
**[[1ls5]] - PfPlm IV + pepstatin derivative<br /> | **[[1ls5]] - PfPlm IV + pepstatin derivative<br /> | ||
+ | |||
+ | *Plasmepsin V | ||
+ | |||
+ | **[[6c4g]] – PvPlm V + inhibitor<br /> | ||
*Proplasmepsin II | *Proplasmepsin II | ||
Line 46: | Line 50: | ||
**[[1pfz]], [[5bwy]] - PfProPlm II<br /> | **[[1pfz]], [[5bwy]] - PfProPlm II<br /> | ||
**[[1miq]] – PvProPlm II – ''Plasmodium vivax''<br /> | **[[1miq]] – PvProPlm II – ''Plasmodium vivax''<br /> | ||
- | **[[1qs8]], [[5i70]] - PvPlm | + | **[[1qs8]], [[5i70]] - PvPlm II + pepstatin derivative<br /> |
}} | }} | ||
== References == | == References == | ||
<references/> | <references/> | ||
[[Category:Topic Page]] | [[Category:Topic Page]] |
Revision as of 07:43, 22 August 2018
|
3D structures of plasmepsin
Updated on 22-August-2018
References
- ↑ Bernstein NK, Cherney MM, Loetscher H, Ridley RG, James MN. Crystal structure of the novel aspartic proteinase zymogen proplasmepsin II from plasmodium falciparum. Nat Struct Biol. 1999 Jan;6(1):32-7. PMID:9886289 doi:10.1038/4905
- ↑ Huizing AP, Mondal M, Hirsch AK. Fighting malaria: structure-guided discovery of nonpeptidomimetic plasmepsin inhibitors. J Med Chem. 2015 Jul 9;58(13):5151-63. doi: 10.1021/jm5014133. Epub 2015 Mar 17. PMID:25719272 doi:http://dx.doi.org/10.1021/jm5014133
- ↑ Jaudzems K, Tars K, Maurops G, Ivdra N, Otikovs M, Leitans J, Kanepe-Lapsa I, Domraceva I, Mutule I, Trapencieris P, Blackman MJ, Jirgensons A. Plasmepsin inhibitory activity and structure-guided optimization of a potent hydroxyethylamine-based antimalarial hit. ACS Med Chem Lett. 2014 Jan 13;5(4):373-7. doi: 10.1021/ml4004952. eCollection, 2014 Apr 10. PMID:24900843 doi:http://dx.doi.org/10.1021/ml4004952
Proteopedia Page Contributors and Editors (what is this?)
Michal Harel, Alexander Berchansky, Joel L. Sussman, Jaime Prilusky